List of Posters
A list of moderated posters are available here.
IgA vasculitis
Miho Miyauchi: A comparative study of clinical and pathological differences between adult-onset IgA vasculitis and IgA nephropathy
Junjun Zhang: Efficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study
Natural history, epidemiology & risk prediction
Stanley Almeida Araújo: Clinical and Pathological Profile of IgA Nephropathy in Brazil: Analysis of 2,207 Renal Biopsies
Bobby Chacko: Characterisation of IgA Nephropathy in an Australian Cohort
Cheng-Hsu Chen: Urinary Galactose-Deficient IgA1 as a Potential Early Biomarker for IgA Nephropathy
Keita Hirano: KDIGO chronic kidney disease risk category and renal survival in patients with IgA nephropathy
Shiko Honma: Utility of A/C subclassification of histological grade classification of IgA nephropathy: a Japanese prospective cohort study
Toshiki Kano: Microscopic hematuria is an early hallmark of IgA nephropathy and an indicator of disease activity
Sayumi Kawamura: Validation of International risk-prediction tool and its Comparison with the JSN Classification in Japanese Patients with IgA Nephropathy: A Retrospective Cohort Study
Kirill Komissarov: Serum IgE is biomarker of benign course of IgA nephropathy
Nicolas Maillard: Clinical Validation of an IgA1 Galactose-Deficient Assay Kit in IgA Nephropathy
Dita Maixnerova: Outcome of Czech patients with IgA nephropathy
Laila-Yasmin Mani: Characteristics and outcome of immunoglobulin A nephropathy – a Swiss single center experience
Masahiro Muto: The clinical impact of glomerular C3 depositions on the severity and treatment responses in IgA nephropathy
Sasikiran Nunna: Healthcare resource utilization and costs among patients with primary immunoglobulin A nephropathy (IgAN) by proteinuria and kidney function decline in China
William J. Placzek: Serum galactose-deficient IgA1 levels in patients with IgA nephropathy and healthy controls measured with GalD®, a novel lectin-based enzyme-linked immunosorbent assay
Anna Popova: Gut Microbiome Features in IgA Nephropathy Patients with Favorable and Unfavorable Prognosis
Paediatric disease
Luca Antonucci: Alternative budesonide formulation in pediatric IgA Nephropathy as a possible therapeutic option: a case series
Luca Antonucci: Secondary IgA Nephropathy in the context of disseminated tuberculosis: a pediatric case report
Stephen Nolan: An open-label phase 3 study of ravulizumab in pediatric immunoglobulin A nephropathy or immunoglobulin A vasculitis-associated nephritis
Liping Rong: Exploration influence of the intensity of renal immune cell infiltration on clinicopathological features and prognosis in children with IgA nephropathy
Fengjie Yang: A pilot study on protective effect of ambrisentan on proteinuria in pediatric patients with IgA nephropathy or IgA vasculitis nephritis
Lan Yang: The efficacy of Nefecon in the treatment of IgA nephropathy and IgA vasculitis nephritis: first-in-pediatrics case series
Xiaohong Zheng: Correlation of capillary loop IgA deposition with clinicopathological features in pediatric IgA nephropathy
Xuhui Zhong: Nefcon Use in Pediatric IgA Nephropathy: Three Case Reports
Pathogenesis
Altynay Balmukhanova: When it is not IgA nephropathy: a case highlighting the diagnostic value of renal biopsy
Ann Chen: Combination of a mouse monoclonal antibody and a GalNAc-specific lectin for monitoring of IgA nephropathy
Kensuke Joh: The Role of T Nodule in the Tonsil-Glomerular Axis in Patients with IgA Nephropathy: A Retrospective Cohort Study
Shuk-Man Ka: Competitive Binding Between IgA and IgG Autoantibodies to Gd-IgA1 Derived from the Same IgA Nephropathy Patient
Eriko Kosuge: Analysis of renal lymph node revealed the presence of IgG+ germinal center B cells in IgA nephropathy model mice
Tzu-Yu Liu: Targeting human IgA autoantibodies and galactose-deficient IgA1 antigen to unravel their pathogenic roles in IgA nephropathy
Lea Novak: Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits in patients with IgA nephropathy and IgA vasculitis with nephritis
Sandra Romero-Ramirez: Evaluation of IgA1 and IgA2 coating patterns of the gut microbiota of IgA Nephropathy patients
Francesco Paolo Schena: Longitudinal blood single-cell RNA sequencing study in IgAN patients from the randomized cligan trial (RCT)
Kazuo Takahashi: Dextran sulfate sodium-induced chronic inflammatory colitis reduces intestinal propionate and causes glomerular IgA-IgG deposition in HIGA mice
Hernan Trimarchi: Moving from the four- to the five-hit hypothesis in IgA nephropathy. A proposal based on novel pathophysiological concepts with potential therapeutic implications
Xinfang Xie: Exploration of the IgA1 O-glycoforms profile and pathogenic IgA-complex compositions by mass spectrum in IgA nephropathy
Transplantation
Guisen Li: Telitacicept Treatment for Recurrent IgA Nephropathy after Kidney Transplantation
Treatment
Ryousuke Aoki: Single-center outcomes and clinical features of persistent urinary abnormalities after tonsillectomy and steroid pulse therapy in IgA nephropathy
Jonathan Barratt: AFFINITY study: 1 year results of atrasentan in IgAN in patients with UPCR <1 and ≥1g/g
Jonathan Barratt: Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial
Jonathan Barratt: Efficacy of nefecon by baseline eGFR deciles: a subanalysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN
Jonathan Barratt: Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard-of-care therapy in primary IgA nephropathy: Week 48 results from a phase 1b study
Shasha Chen: Budesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases
shasha Chen: Efficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study
Ming Cheng: Beyond Nine Months: Real-World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy
Chee Kay Cheung: Sparsentan as first-line treatment of incident patients with IgA nephropathy: An interim analysis of the SPARTAN trial evaluating efficacy and cardiovascular risk variables
Ming Fang: Efficacy and Safety of Finerenone in Immunoglobulin A Nephropathy: A 12-months Real-World Observational Study
Ming Fang: Nefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study
Jürgen Floege: Felzartamab for IgA nephropathy: final results of the IGNAZ study
Hiddo J. L. Heerspink: ALIGN post-hoc analyses: Reduction in proteinuria with atrasentan across subgroups by MEST-C score, baseline hematuria and baseline UPCR
Nozomi Kadota: Is IgA nephropathy a curable disease? ~case series of repeat biopsy~
Sai Ram Keithi Reddy: Immunosuppressive Therapy in IgA Nephropathy Associated with Chronic Liver Disease
Komiljon Khamzaev: Effects of cyclosporin a therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy
Laura Kooienga: Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart
Laura Kooienga: Zigakibart-treated patients with IgAN achieved high rates of proteinuria remission and stable eGFR over 76 weeks in a Phase 1/2 study
Richard Lafayette: Impact of sustained UPCR reduction on eGFR over 2 years: a secondary analysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN
Richard Lafayette: Impact of time since diagnosis on eGFR and UACR changes over time with nefecon: a subanalysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN
Richard Lafayette: UPCR response at 12 months in patients with IgAN receiving nefecon vs placebo: analysis of NefIgArd trial data
Selvin Sundar Raj Mani: Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven IgAN: Multi-center, Multi-arm and Multi-stage - Design Innovations and Operational Feasibility in Resource-Limited Settings
Stephen Nolan: Spot and 24-hour assessments of proteinuria and albuminuria in IgA nephropathy: A prespecified analysis of the SANCTUARY trial
Sasikiran Nunna: Treatment patterns and healthcare resource utilization among adults with primary IgA nephropathy (IgAN) in China: a longitudinal retrospective cohort study from a multi-province registry
Vlado Perkovic: Evaluating sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study
Dana V. Rizk: A mechanistic biopsy study of the effect of iptacopan on immunopathology in patients with IgA nephropathy (IgAN)
Dana V. Rizk: Safety and efficacy of iptacopan in patients with IgA nephropathy (IgAN) with baseline eGFR 20-<30 mL/min: Phase 3 APPLAUSE-IgAN subcohort results
Millie Shah: Felzartamab durably reduces disease relevant biomarkers through targeting of CD38+ plasma cells and plasmablasts, the upstream drivers of IgA nephropathy
Sydney CW Tang: Concomitant sparsentan (SPAR) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in adults with IgA nephropathy (IgAN) in the phase 2 SPARTACUS trial
Xiaoyan Xiao: Early Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function
Last update on 15 July 2025.
The programme might be subject to necessary changes.
